

ATTORNEY DOCKET NO. 14014.0349U2 PATENT APPLICATION No. 10/049,586

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| In re application of |) | |
|--------------------------------------|-----|-------------------------|
| Blackshear et al. |) (| Group Art Unit: 1634 |
| Serial No. 10/049,586 |) | |
| |) 1 | Examiner: Sisson, B. L. |
| Filed: February 12, 2002 |) | |
| |) (| Confirmation No. 9700 |
| For: TTP-RELATED ZINC FINGER DOMAINS |) | |
| AND METHODS OF USE |) | |

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C. Customer No. 36339

Sir:

Pursuant to the requirements of 37 C.F.R. § 1.56, submitted herewith on the accompanying Information Disclosure Statement List is a listing of documents known to Applicants and/or their attorneys.

This Information Disclosure Statement is believed to be filed in a timely manner pursuant to 37 C.F.R. § 1.97(c), in that neither a final Office Action nor a Notice of Allowance has been mailed to Applicants. Accordingly, Applicants enclose the fee required under 37 C.F.R. § 1.97(c)(2).

Consideration of the cited documents and making the same of record in the prosecution of the above-referenced application are respectfully requested.

03/30/2005 MBLANCO 00000001 10049586

01 FC:1806

180.00 OP

ATTORNEY DOCKET NO. 14014.0349U2 PATENT APPLICATION No. 10/049,586

A Credit Card Payment Form PTO-2038 authorizing payment check in the amount of \$180.00, representing the fee under 37 C.F.R. § 1.17(p), is enclosed. This amount is believed to be correct; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.

Gwendolyn D. Spratt Registration No. 36,016

NEEDLE & ROSENBERG, P.C. Customer Number 36339 (678) 420-9300 (678) 420-9301 (fax)

| CEDTIFICATE (| r Evance ! | MAILING UNDER | 27 C E D | C 1 10 |
|---------------|--------------|----------------|-----------|----------|
| CERTIFICATEO |)F EXPRESS I | VIAILING UNDER | 3/ C.F.R. | . 0 1.10 |

I hereby certify that this correspondence and any items indicated as attached or included are being deposited with the United States Postal Service as Express Mail Label No. EL970612199US in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, A 22313-1450, on the data indicated below.

Scott Darnell

Date

3-28-05

ATTORNEY DOCKET NO. 14014.0349U2 APPLICATION NO. 10/049,586 SHEET 1 OF 5

INFORMATION DISCLOSURE STATEMENT LIST

| | Complete if Known |
|----------------------|-------------------|
| Application Number | 10/049,586 |
| Filing Date | February 12, 2002 |
| First Named Inventor | Blackshear et al. |
| Group Art Unit | 1634 |
| Everniner Neme | Siecon D.I |

| | (Ose as many sneets as necessary) | | | | 1634 | 1034 | | |
|------------------------|-----------------------------------|--|--|------------|----------------------------|-----------------------|--|---|
| | | | Examiner Name | | Siss | Sisson, B.L. | | |
| U.S. PATENT DOCUMENTS | | | | | | | | |
| Examiner's Initials | Cite No. | Document No. | Date | | | Class | Subclass | Filing Date (if appropriate |
| | | | | | | | | |
| | | | FOREIG | IN PA | TENT DOCUM | ENTS | <u> </u> - - - - - - - - - - - - - | |
| Examiner's | Cite | Foreign Patent Docum | | | Nan | | Translation Yes/No | |
| Initials | No. | Country Code-Number-Kind C | | | | | | |
| | | | | | | | | |
| | Ha | | NON | -PATE | NT DOCUMEN | TS. | | |
| Examiner's Initials | Cite No. | | Non-Patent Cita | tions (ind | ude Author, Title, Publish | er, Relevant F | Pages, Date and | Place of Publication) |
| | B1. | | septic shock | . A ran | | | | e treatment of patients with al. Ro 45-2081 Study Group." |
| | B2. | Achsel and Shimur | ra, "Factors i | nvolve | | | | plicing from downstream |
| | B3. | Agui et al., Stimula | splicing enhancers." J Biochem (Tokyo). 1996 Jul;120(1):53-60. Agui et al., Stimulation of interleukin-6 production by endothelin in rat bone marrow-derived stromal cells. Blood 84:2531, 1994 | | | | | |
| | B4. | Antman et al.,: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N. Engl. J. Med. 319:593, 1988 | | | | | | |
| | B5. | Baker EJ, Liggit P: Accelerated poly(A) loss and mRNA stabilization are independent effects of protein | | | | | | |
| | B6. | | synthesis inhibition on alpha-tubulin mRNA in Chlamydomonas. Nuc. Acids. Res. 21:2237, 1993 Beelman and Parker: Degradation of mRNA in eukaryotes. Cell 81:179, 1995 | | | | | |
| | B7. | Beelman and, Parker: Differential effects of translational inhibition in cis and in trans on the decay of the unstable yeast MFA2 mRNA. J. Biol. Chem. 269:9687, 1994 | | | | | | |
| | B8. | Bentley, SA: The role and composition of the adherent layer in long-term bone marrow culture. In: Long term bone marrow culture: proceedings of a symposium held at the Kroc Foundation. Kroc Foundation Series, vol.18. Alan R. Liss, Inc. New York. 1984 | | | | | | |
| | B9. | Beutler "TNF, immunity and inflammatory disease: lessons of the past decade." J Investig Med. 1995 Jun;43(3):227-35. | | | | | | |
| | B10. | Beutler B. and T. Brown, "A CAT reporter construct allows ultrasensitive estimation of TNF synthesis, and suggests that the TNF gene has been silenced in non-macrophage cell lines." J Clin Invest. 1991 Apr;87(4):1336-44. | | | | | | |
| | B11. | Blackshear, P.J. 1984. Systems for polyacrylamide gel electrophoresis. Methods Enzymol. 104:237-255. | | | | | | |
| | B12. | Carballo et al., Phagocytic and macropinocytic activity in MARCKS-deficient macrophages and fibroblasts. Am. J. Physiol. 277:163, 1999 | | | | cient macrophages and | | |
| | B13. | Cheng et al. "Cach alpha transgenic m | | | | | nanges in | keratin promoter-driven TNF |
| | B14. | Clements et al., "Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factoralpha inhibitor." J Neuroimmunol. 1997 Apr;74(1-2):85-94. | | | | | | |
| Examiner | Signatu | re: | 0 | ate Co | nsidered: | | | |

| Examiner Signature: | [|
|---------------------|-----|
| | - 1 |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ATTORNEY DOCKET NO. 14014.0349U2 **APPLICATION NO. 10/049,586** SHEET 2 OF 5

INFORMATION DISCLOSURE

| | Complete if Known |
|----------------------|-------------------|
| Application Number | 10/049,586 |
| Filing Date | February 12, 2002 |
| First Named Inventor | Blackshear et al. |
| Group Art Unit | 1634 |
| Examiner Name | Sisson B I |

| 317 | ATEMENT LIST | Filing Date | February 12, 2002 | | |
|---------|--|-----------------------------|---|--|--|
| | | First Named Inventor | Blackshear et al. | | |
| (Use as | many sheets as necessary) | Group Art Unit | 1634 | | |
| | | Sisson, B.L. | | | |
| B15. | Examiner Name Sisson, B.L. Derigs et al.,: Granulocyte-macrophage colony-stimulating factor expression is regulated at | | | | |
| | 22:924, 1994 | | e bone marrow stromal cell line. Exp. Hematol | | |
| B16. | Physiol. 91:335, 1976 | | naemopoietic stem cells in vitro. J. Cell. | | |
| B17. | | | nd production of differentiated progeny in n vitro. J. Exp. Med. 145:1612, 1977 | | |
| B18. | receptor-2-deficient mice. Natu | re 372:560, 1994 | is factor but normal T-cell development in TNI | | |
| B19. | Flach, et al.,. 1994. A yeast RN Mol. Cell. Biol. 50:1-12. | NA-binding protein shuttl | les between the nucleus and the cytoplasm. | | |
| B20. | Fu, X. D. "The superfamily of ar | ginine/serine-rich splicin | ng factors." RNA. 1995 Sep;1(7):663-80. | | |
| B21. | | clinical applicability of h | nage colony stimulating factor reduces nigh dose cyclophosphamide treatment in | | |
| B22. | Godfrey K., "Statistics in practice 5;313(23):1450-6. | e. Comparing the means | s of several groups." N Engl J Med. 1985 Dec | | |
| B23. | | | EGF-inducible gene indicates the existence of 1081-1083. | | |
| B24. | Gozani et al., "A potential role for U2AF-SAP 155 interactions in recruiting U2 snRNP to the branch site." Mol Cell Biol. 1998 Aug;18(8):4752-60. | | | | |
| B25. | | orticosteroid-dependent | insulin-resistant lipogenesis in marrow 175:752, 1978 | | |
| B26. | | nent of tumor necrosis fa | actor mRNA by an endotoxin-inducible | | |
| B27. | | the tumor necrosis fact | or promoter and 3'-untranslated regions." | | |
| B28. | | of tumor necrosis factor | mRNA turnover in lipopolysaccharide- ug 27;1090(1):22-8. | | |
| B29. | | nase inhibitor prevents | lethal acute graft-versus-host disease in | | |
| B30. | Hel et al., 1996. Two distinct remains many form complexes with many | | ted region of tumor necrosis factor alpha . Cell. Biol. 16:5579-90. | | |
| B31. | | | roteins forming complexes with a novel A. Nucleic Acids Res. 26:2803-2812. | | |
| B32. | | | A expression in HL-60 cells." Lymphokine Re | | |
| B33. | | | 0/G1 switch gene homologous to a rodent tor. DNA & Cell Biol. 12:73-88. | | |
| B34. | | e of tumor necrosis facto | or in murine and human autoimmunity." J | | |
| B35. | Jorres A. et al.," Inhibition of tumour necrosis factor production in endotoxin-stimulated human mononuclear leukocytes by the prostacyclin analogue iloprost: cellular mechanisms." Cytokine. 1997 Feb;9(2):119-25. | | | | |

| Examiner Signature: | Date Considered: | - |
|---------------------|------------------|---|
| | | |
| | | |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



ATTORNEY DOCKET NO. 14014.0349U2 APPLICATION NO. 10/049,586 SHEET 3 OF 5

INFORMATION DISCLOSURE STATEMENT LIST

| | Complete if Known |
|----------------------|-------------------|
| Application Number | 10/049,586 |
| Filing Date | February 12, 2002 |
| First Named Inventor | Blackshear et al. |
| Group Art Unit | 1634 |
| Evaminer Name | Sisson R I |

| | | First Named Inventor | Blackshear et al. | | |
|---------|---|----------------------------|---|--|--|
| (Use as | many sheets as necessary) | Group Art Unit | 1634 | | |
| | | Examiner Name | Sisson, B.L. | | |
| B36. | Katz et al., 1994, AU-A, an RN | A-binding activity distinc | t from hnRNP A1, is selective for AUUUA | | |
| | repeats and shuttles between the nucleus and the cytoplasm. Nucleic Acids Res. 22:238-46. | | | | |
| B37. | | | ur necrosis factor: a predictive genetic model | | |
| | of arthritis." EMBO J. 1991 Dec; | | | | |
| B38. | Klausner et al., Cell 72, 19 (199 | | 413 (1993). | | |
| B39. | | | odulation of myeloid colony-stimulation factor | | |
| | expression by tumor necrosis fa | | | | |
| B40. | | | g and protein surveillance. Methods in | | |
| | Enzymology 194:508-519. | | • | | |
| B41. | Lai et al.,: Rapid insulin-stimulat | ted accumulation of an n | nRNA encoding a proline-rich protein. J. Biol | | |
| | Chem. 265:16556, 1990 | | • . | | |
| B42. | Lai, et al., 1998. Characteristics | s of the intron involveme | nt in the mitogen-induced expression of Zfp- | | |
| | 36. J. Biol. Chem. 273:506-517 | 7. | | | |
| B43. | Lai, et al.,. 1995. Promoter and | alysis of Zfp-36, the mito | gen-inducible gene encoding the zinc finger | | |
| | protein tristetraprolin. J. Biol. Cl | | | | |
| B44. | , | • | complex disease of GM-CSF transgenic | | |
| | mice. Growth Factors 6:131, 19 | | | | |
| B45. | | | ence required for lipopolysaccharide-induced | | |
| | binding of a 55-kDa protein on the | umor necrosis factor n | nRNA. J. Biol. Chem. 273:13781-13786. | | |
| B46. | Lobach et al., "Nucleotide seque | ence, expression, and ch | nromosomal mapping of Mrp and mapping of | | |
| | five related sequences." Genom | | | | |
| B47. | Lorenz H. M. et al., "In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal | | | | |
| | | | . Short term cellular and molecular effects." J | | |
| | Immunol. 1996 Feb 15;156(4):1 | | | | |
| B48. | | a TIS11 homologue enc | odes a developmentally regulated gene. | | |
| | Oncogene 9:3329-3334. | | | | |
| B49. | | | ence for the predicted protein from the | | |
| | mitogen-inducible TIS11 primary | | | | |
| B50. | | otein and germline spec | cification in C. elegans embryos. Nature | | |
| | 382:710-712. | | | | |
| B51. | | | tallothionein mRNA poly(A)-shortening using | | |
| | RNA blot hybridization. Nucleic | | | | |
| B52. | • | | al reveals interaction between U2AF35 and | | |
| | the 3' splice site AG." Nature. 19 | | | | |
| B53. | | | nase inhibitor, exerts its antidiabetic effect by | | |
| | inhibiting tumor necrosis factor-alpha production." Life Sci. 1997;61(8):795-803. | | | | |
| B54. | Natesan et al., 1997. Transcript | | | | |
| B55. | | etic growth factors in ma | arrow transplantation. Curr. Opin. Oncol. | | |
| 550 | 6:139, 1994 | | | | |
| B56. | | | osis in Ramos human B cells by signalling | | |
| | | | on of an early response gene, Berg36." | | |
| | Biochem Soc Trans. 1997 May; | | | | |
| B57. | Odeh "The role of tumour necrosis factor-alpha in acquired immunodeficiency syndrome." J Intern Med. 1990 Dec;228(6):549-56. | | | | |
| | | | | | |

| Exam | | |
|------|--|--|
| | | |
| | | |

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



ATTORNEY DOCKET NO. 14014.0349U2 APPLICATION NO. 10/049,586 SHEET 4 OF 5

| DEMA | 2 Y | Complete if Known |
|--|--------------------------|---------------------------------------|
| INFORMATION DISCLOSURE | Application Number | 10/049,586 |
| STATEMENT LIST | Filing Date | February 12, 2002 |
| | First Named Inventor | Blackshear et al. |
| (Use as many sheets as necessary) | Group Art Unit | 1634 |
| | Examiner Name | Sisson, B.L. |
| B58. Otsuka et al., 1988. Isolation an | d characterization of an | expressible cDNA encoding human IL-3. |

| H | | Tilst Named inventor | Diackshear et al. | |
|---|--|------------------------------|--|--|
| (Use as r | many sheets as necessary) | Group Art Unit | 1634 | |
| | | Examiner Name | Sisson, B.L. | |
| B58. | Otsuka et al., 1988. Isolation ar Induction of IL-3 mRNA in huma | | n expressible cDNA encoding human IL-3. unol. 140:2288-2295. | |
| B59. | | | | |
| B60. | | | | |
| B61. | | | | |
| | | | | |
| B63. Rubin HN, Halim MN: Stimulation of globin synthesis by 11-amino acid peptide. Int. 31:267, 1993 | | | · | |
| B64. | Sachs, "Messenger RNA degrad | dation in Eukaryotes" ell | 74:413-421 (1993) | |
| B65. Schuler GD, Cole MD: GM-CSF and oncogene mRNA stabilities are independen in a mouse monocytic tumor. Cell 55:1115, 1988 B66. Seydoux et al.,. 1996. Repression of gene expression in the embryonic germ lir Nature 382:713-716. | | | · · · | |
| | | | in the embryonic germ lineage of C. elegans. | |
| B67. | | | | |
| B68. | | | | |
| B69. | Shi Y. et al., J. Biol. Chem. 272, 29290 (1997). | | | |
| B70. Shyu et al., "The c-fos transcript is targeted for rapid decay by two distinct mRNA deg pathways." Genes Dev. 1989 Jan;3(1):60-72. B71. Solorzano et al., "A matrix metalloproteinase inhibitor prevents processing of tumor no alpha (TNF alpha) and abrogates endotoxin-induced lethality." Shock. 1997 Jun;7(6): B72. Spriggs et al., "Phospholipase A2 activation and autoinduction of tumor necrosis factor expression by tumor necrosis factor." Cancer Res. 1990 Nov 15;50(22):7101-7. B73. Stanley et al., The structure and expression of the murine gene encoding granulocyte colony stimulating factor: evidence for utilization of alternative promoters. EMBO J. 4 | | | cay by two distinct mRNA degradation | |
| | | | | |
| | | | luction of tumor necrosis factor gene | |
| | | | ne gene encoding granulocyte-macrophage | |
| B74. | | | | |
| B75. | | | | |
| B76. | | | | |
| B77. Taylor et al., A pathogenetic role for TNFα in the syndrome of cachexia, arthritis, at resulting from tristetraprolin (TTP) deficiency. Immunity 4:445, 1996 B78. Taylor et al.,: Mitogens stimulate the rapid nuclear to cytosolic translocation of trister potential zinc-finger transcription factor. Mol. Endocrinol. 10:140, 1996 | | | | |
| | | | osolic translocation of tristetraprolin, a | |
| B79. | Taylor et al.,: Phosphorylation of | f tristetraprolin, a potenti | ial zinc finger transcription factor, by mitogen in kinase in vitro. J. Biol. Chem. 270:13341, | |

| Examiner Signature: | Date Considered: | | |
|--|------------------|--|--|
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |



ATTORNEY DOCKET NO. 14014.0349U2 APPLICATION NO. 10/049,586 SHEET 5 OF 5

INFORMATION DISCLOSURE STATEMENT LIST

| ١ | | Complete if Known | |
|---|----------------------|-------------------|--|
| | Application Number | 10/049,586 | |
| | Filing Date | February 12, 2002 | |
| | First Named Inventor | Blackshear et al. | |
| | Group Art Unit | 1634 | |
| | Examiner Name | Sisson, B.L. | |

| (| (Use as many sheets as necessary) | | Group Art Unit | 1634 | | |
|---|-----------------------------------|---|---------------------------|--|--|--|
| | | | Examiner Name | Sisson, B.L. | | |
| | B80. | te Kronnie et al.,. "Zebrafish CTI embryos." Dev Genes Evol. 199 | | otein, is expressed in ovarian oocytes and | | |
| B81. Thorens et al., Phagocytosis a through posttranscriptional reg B82. Tso et al., Isolation and characteristics. | | | d inflammatory stimuli ir | nduce GM-CSF mRNA in macrophages | | |
| | | | | an glyceraldehyde-3-phosphate lar evolution of the gene. Nucl. Acids Res. | | |
| | B83. | Ulich et al.,. "Haematologic effects of TNF." Res Immunol. 1993 Jun;144(5):347-54. | | | | |
| | B84. | | | | | |
| | B85. | | | es of liver, spleen and bone marrow at o maintain GM-CFC proliferation. Exp. | | |
| | B86. | | | | | |
| | B87. | | | | | |
| | B88. | Vogel et al.,: Induction of colony stimulating factor in vivo by recombinant interleukin 1α and recombinant tumor necrosis factor α . J. Immunol. 138:2143, 1987 | | | | |
| | B89. | Wodnar-Filipowicz A, Moroni C: Regulation of interleukin 3 mRNA expression in mast cells occurs at the posttranscriptional level and is mediated by calcium ions. Proc. Natl. Acad. Sci. USA 87:777, 1990 | | | | |
| | B90. | Worthington et al., 1996. Metal binding properties and secondary structure of the zinc-binding domain of Nup475. Proc. Natl. Acad. Sci. USA 93:13754-13759. | | | | |
| | B91. | Wu et al., "Neural tube defects and abnormal brain development in F52-deficient mice." Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2110-5. | | | | |
| | B92. | Xu et al., "Modulation of the fate of cytoplasmic mRNA by AU-rich elements: key sequence features controlling mRNA deadenylation and decay." Mol Cell Biol. 1997 Aug;17(8):4611-21. | | | | |
| | B93. | | | | | |
| | B94. | | | | | |
| | B95. | Zoja et al., : Interleukin-1 β and tumor necrosis factor- α induce gene expression and production of leukocyte chemotactic factors, colony-stimulating factors, and interleukin-6 in human mesangial cells. Am. J. Pathol. 138:991, 1991 | | | | |
| | B96. | | | | | |
| | B97. | | factor U2AF35 mediates | s critical protein-protein interactions in Dev. 1996 Jun 1;10(11):1356-68. | | |

| Examiner Signature: | Date Considered: |
|--|---|
| | |
| EXAMINER: Initial if reference considered, whether or no | at citation is in conformance with MPEP 609. Draw line through citation if not in |